founder-mode-oncology

Design a personalized cancer treatment strategy by integrating maximal diagnostics, parallel therapeutic development, and real-time monitoring. This framework requires genomic, transcriptomic, and liquid biopsy data to orchestrate a systematic, data-driven approach for patient-specific therapeutic combinations.

Parallel therapeutic development in personalized oncology is the simultaneous design of patient-specific treatments. It guides the creation of personalized neoantigen vaccines, radioligand therapies, and immune modulators while navigating FDA expanded access protocols.

ctDNA monitoring adapts immunotherapy by implementing a rigorous tracking cadence alongside serial scRNA-seq. This real-time monitoring measures patient response and facilitates immediate treatment adaptations based on circulating tumor DNA levels.

Yes, you can use this framework to design neoantigen vaccines from scRNA-seq and WGS data. The maximal diagnostics pillar orchestrates a comprehensive diagnostic stack to identify non-obvious therapeutic targets for patient-specific vaccine development.

To navigate personalized cancer treatment combinations, you need access to genomic, transcriptomic, and liquid biopsy data. This multi-modal data executes the three-pillar oncology methodology for maximal diagnostics and real-time monitoring.

Use a radioligand therapy framework for oncology cases requiring personalized combinations alongside neoantigen vaccines and immune modulators. It is indicated when comprehensive diagnostic stacks identify specific non-obvious therapeutic targets for parallel development.